


PHARMACEUTICAL 2020

AKCEA THERAPEUTICS INC. Rank 16 of 362







RealRate

PHARMACEUTICAL 2020

AKCEA THERAPEUTICS INC. Rank 16 of 362

The relative strengths and weaknesses of AKCEA THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AKCEA THERAPEUTICS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 600% points. The greatest weakness of AKCEA THERAPEUTICS INC. is the variable Research and Development, reducing the Economic Capital Ratio by 23% points.

The company's Economic Capital Ratio, given in the ranking table, is 233%, being 536% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	496,905
Cost of Goods Sold	0
Intangible Assets	83,051
Liabilities, Current	41,998
Liabilities, Non-Current	14,248
Other Assets	14,033
Other Compr. Net Income	329
Other Expenses	-21,872
Other Liabilities	0
Other Net Income	4,890
Property and Equipment	5,261
Research and Development	292,852
Revenues	488,543
Selling, General and Administrative Expense	181,681

Output Variable	Value in 1000 USD
Assets	599,250
Liabilities	56,246
Expenses	452,661
Stockholders Equity	543,004
Net Income	40,772
Comprehensive Net Income	40,936
Economic Capital Ratio	233%

